Skip Navigation


JAC Advance Access originally published online on March 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(5):811-812; doi:10.1093/jac/dki072
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/811    most recent
dki072v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petinaki, E.
Right arrow Articles by Maniatis, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petinaki, E.
Right arrow Articles by Maniatis, A. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Correspondence

Emergence of Staphylococcus hominis strains expressing low-level resistance to quinupristin/dalfopristin in Greece

E. Petinaki1,*, I. Spiliopoulou2, M. Maniati1 and A. N. Maniatis1

1 Department of Microbiology, School of Medicine, University of Thessalia, Papakyriazi 22, Larissa; 2 Department of Microbiology, School of Medicine, University of Patras, Patras, Greece

* Corresponding author. Fax: +30-41-0682508; Email: petinaki@hotmail.com

Keywords: streptogramins , staphylococci , resistance , Greece

The first 10% of the full text of this article appears below.

Sir,

Quinupristin/dalfopristin, a semi-synthetic derivative of pristinamycin IA (streptogramin B) and pristinamycin IIA (streptogramin A), respectively, was introduced in Greek hospitals in 2002, for the treatment of infections caused by multiresistant Gram-positive bacteria such as vancomycin-resistant enterococci and teicoplanin-resistant staphylococci. In Greece, where natural mixtures (pristinamycin, synergistin, etc.) have not been used orally and topically, and virginiamycin has been never used as a growth promoter in animal feed, staphylococci resistant to streptogramins were not isolated until 2002.1 This is the first report of the emergence of staphylococci resistant to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?